1884.9000 -15.10 (-0.79%)
NSE Nov 20, 2026 15:31 PM
Volume: 1.9M
 

1884.90
-0.79%
Deven Choksey
Sun Pharma’s outlook remains strong, driven by high-margin and innovative products. India growth will be led by new launches and upcoming GLP-1 therapies, EM by branded generics, and RoW by complex products. In the U.S., momentum will be supported by LEQSELVI ramp-up, Unloxcyt launch, and continued strength in ILUMYA and CEQUA.
Sun Pharmaceutical I.. has an average target of 2077.88 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended